Antibiotic Therapy

Atrix Laboratories announced that it seeks marketing approval from the Food and Drug Administration for its Atridox drug product for the treatment of periodontal disease.

Jun 1st, 1997

Atrix Laboratories announced that it seeks marketing approval from the Food and Drug Administration for its Atridox drug product for the treatment of periodontal disease.

- The company submitted a New Drug Application to the FDA April 1.

- A spokesperson for the company said Atridox is a non-invasive therapy that is faster and less painful than mechanical scaling and root planing.

- Pending regulatory approval, the Atridox product will be marketed in North America and certain European countries by Block Drug Co.

- For more information, contact Atrix Laboratories, Inc., 2579 Midpoint Drive, Fort Collins, CO 80525; www.atrixlabs.com.

More in Home